Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer

Table 1

Patient characteristics $(N=44).$

			N (%)
Age, years	Median	63.0
	Range	33–81
Sex	Male		31 (70.5%)
	Female		13 (29.5%)
ECOG performance status	0		24 (54.5%)
	1		15 (34.1%)
	2		5 (11.4%)
Primary site	Colon		22 (50.0%)
	Rectum		20 (45.5%)
	Colorectal		2 (4.5%)
Metastatic sites	Liver		31 (70.5%)
	Lung		18 (40.9%)
	Lymph nodes		8 (18.2%)
	Other (mediastinum, pelvis, perineum)		4 (9.1%)
	Peritoneum		2 (4.5%)
Number of target lesions	1		11 (25.0%)
	2		12 (27.3%)
	3		10 (22.7%)
	4 or more		11 (25.0%)
Prior therapy	Surgery		38 (86.4%)
	Radiotherapy		11 (25.0%)
	Chemotherapy
	Metastatic		44 (100.0%)
Time from initial diagnosis to inclusion, months	Median	17.0
	Range	2.8–81.1

Abbreviation: ECOG: Eastern Cooperative Oncology Group.